VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE
May 12, 2000
Slides
Introduction and Interim Policy, Dr. Andrew Lewis, FDA
CBER Research Related to Neoplastic Cell Lines, Dr. Philip krause, FDA